FDA Output
FDA Output, April 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in April 2026. Updated April 13.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Business Strategies
Personalized Medicine is Coming to Chronic Low Back Pain
Low back pain, one of the most prevalent chronic conditions, is in the early stages of moving toward a more stratified, personalized model of care. Large spine companies remain focused on their core, one-size-fits-all businesses, while advances in scientific understanding of pain and technology are creating opportunities for new entrants like Aclarion, Persica Pharma, and Boston Scientific. A first of its kind, the NIH Heal Initiative has laid the groundwork, even as it weathers funding cuts
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
ICYMI
Low Back Pain Treatment Gets Personal
The treatment of low back pain is beginning to move toward a more stratified, personalized model of care. Scientific and technological advances are creating opportunities for new entrants in the market. Excerpted from our recent feature article.